fluorodeoxyglucose f18 has been researched along with pemetrexed in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alloisio, M; Ceresoli, GL; Chiti, A; Incarbone, M; Lutman, RF; Rodari, M; Salamina, S; Santoro, A; Zucali, PA | 1 |
| Schaefer, NG; Seifert, B; Soyka, JD; Stahel, RA; Steinert, HC; Veit-Haibach, P | 1 |
| Schaefer, NG; Soyka, JD; Stahel, RA; Steinert, HC; Veit-Haibach, P | 1 |
| Fujii, K; Ichiyasu, H; Kohrogi, H; Saeki, S; Saita, N; Sakata, S; Sasaki, J; Sato, R | 1 |
| Avril, N; Baccarini, M; Luong, P; Phillips, MM; Sheaff, MT; Stephen, E; Szlosarek, PW; Szyszko, T | 1 |
| Akin, O; Arslan, A; Deniz, E; Ozcakir-Tomruk, C | 1 |
| Fukuhara, M; Hasegawa, T; Higuchi, M; Inoue, T; Owada, Y; Suzuki, H; Watanabe, Y; Yamaura, T | 1 |
| Doi, H; Funaguchi, N; Hasegawa, S; Kanemura, S; Kitajima, K; Kuribayashi, K; Mikami, K; Nakano, T; Shibata, E | 1 |
| Doi, H; Fujimoto, E; Kanemura, S; Kijima, T; Kitajima, K; Kuribayashi, K; Mikami, K; Nakano, T; Negi, Y | 1 |
| Bombardieri, E; Bonifacio, C; Bonomi, M; Ceresoli, GL; Chiti, A; Ciocia, G; De Vincenzo, F; Gianoncelli, L; Giordano, L; Lopci, E; Lorenzi, E; Perrino, M; Santoro, A; Setti, LR; Simonelli, M; Zucali, PA | 1 |
| Aerts, J; Biesma, B; Dingemans, AC; Groen, HJM; Hoekstra, O; Klinkenberg, TJ; Kloosterziel, C; Pieterman, R; Schramel, FMNH; Smit, EF; Smit, HJM; van den Borne, B; van der Heijden, EHFM; van der Noort, V; van Tinteren, H; Verhagen, A | 1 |
| Dubray, B; Ganem, J; Gouel, P; Salaun, M; Texte, E; Thureau, S; Vera, P | 1 |
1 trial(s) available for fluorodeoxyglucose f18 and pemetrexed
| Article | Year |
|---|---|
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nadroparin; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Pneumonectomy; Positron-Emission Tomography | 2019 |
11 other study(ies) available for fluorodeoxyglucose f18 and pemetrexed
| Article | Year |
|---|---|
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorodeoxyglucose F18; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Palliative Care; Pemetrexed; Pleural Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Female; Fluorodeoxyglucose F18; Glutamates; Glycolysis; Guanine; Humans; Male; Mesothelioma; Palliative Care; Pemetrexed; Pleural Neoplasms; Positron-Emission Tomography; Prognosis; Treatment Outcome | 2010 |
Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorodeoxyglucose F18; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Pemetrexed; Pleural Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
FDG-PET and chemotherapy for successful diagnosis and treatment of cardiac metastasis from non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Electrocardiography; Female; Fluorodeoxyglucose F18; Glutamates; Guanine; Heart Neoplasms; Humans; Lung Neoplasms; Middle Aged; Pemetrexed; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argininosuccinate Synthase; Asbestos; Cisplatin; Clinical Trials as Topic; DNA Methylation; Fatal Outcome; Fluorodeoxyglucose F18; Glutamates; Guanine; Humans; Hydrolases; Male; Mesothelioma; Middle Aged; Mutation; Occupational Exposure; Pemetrexed; Pleural Effusion, Malignant; Pleural Neoplasms; Polyethylene Glycols; Positron-Emission Tomography; Promoter Regions, Genetic; Radiopharmaceuticals | 2013 |
A case report of metastasis of malignant mesothelioma to the retromolar trigone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Calbindin 2; Cisplatin; Deoxycytidine; Diagnosis, Differential; Fatal Outcome; Fluorodeoxyglucose F18; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Mouth Neoplasms; Pemetrexed; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Radiography, Panoramic; Radiotherapy, Adjuvant | 2016 |
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cisplatin; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Monitoring, Physiologic; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neutrophil Infiltration; Nivolumab; Pemetrexed; Pneumonectomy; Positron-Emission Tomography; Radiopharmaceuticals | 2016 |
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2017 |
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Positron-Emission Tomography; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Prognostic and predictive role of [
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Neoplasm Staging; Pemetrexed; Pleurodesis; Positron-Emission Tomography; Prognosis; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gamma Rays; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival; Proportional Hazards Models; Radiopharmaceuticals; Remission Induction; Retrospective Studies; Taxoids; Tumor Burden; Vinorelbine | 2019 |